Transgene Biotek Ltd

Transgene Biotek Stock View

(BSE)

2.75

20.84
Proj. ROE (%)
-
Proj. P/E (x)
-
Proj EV / EBITDA (x)
-
Proj. P/BV (x)
-
Proj. Revenue ( Cr.)
-

Stock View

-
Share on
The average score for Transgene Biotek Ltd stands at 3 against 3, three months back.

Transgene Biotek Limited is an India-based biotechnology company. The Company is engaged in a single business segment of Bulk Drugs. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics. The Company offers TrabiAAV, which is a platform for the delivery of micro ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy. It also offers monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-0404, is used for the treatment of metastatic liver cancer. Its TBL-1203, is used to strengthen cell-mediated immunity and complete elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus is a drug that suppresses the immune system and is mainly used to prevent rejection of transplanted organs.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data
50 DMA()
3.03
100 DMA ()
3.19
200 DMA ()
3.41
52 Weeks Range
2.70
4.88
Street View :-
Bearish
Open ZERO Brokerage Demat Account
Open Demat Account

Invest wise with Expert advice

By continuing, I accept the Terms & Conditions and agree to receive updates on Whatsapp